Published in J Clin Microbiol on April 01, 1976
Gelatin neutralization of the inhibitory effect of sodium polyanethol sulfonate on Neisseria meningitidis in blood culture media. J Clin Microbiol (1977) 2.16
Controlled evaluation of the effect of atmosphere of incubation on detection of bacteremia and fungemia in supplemented peptone broth. J Clin Microbiol (1982) 1.81
Inhibition of Neisseria gonorrhoeae by sodium polyanetholesulfonate. J Clin Microbiol (1981) 1.43
Controlled evaluation of blood culture medium containing gelatin and V-factor-analog for detection of septicemia in children. J Clin Microbiol (1988) 1.28
Evaluation of the sodium polyanethol sulfonate disk test for the identification of Peptostreptococcus anaerobius. J Clin Microbiol (1976) 1.24
Rapid detection of bacteremia in children with a modified lysis direct plating method. J Clin Microbiol (1985) 1.12
Comparative evaluation of supplemented peptone broth with sodium polyanetholesulfonate and trypticase soy broth with sodium amylosulfate for detection of septicemia. J Clin Microbiol (1982) 1.10
Inactivation of classical and alternative pathway-activated bactericidal activity of human serum by sodium polyanetholsulfonate. J Clin Microbiol (1977) 1.05
Effect of sodium polyanetholesulfonate and gelatin on the recovery of Gardnerella vaginalis from blood culture media. J Clin Microbiol (1985) 1.05
Effects of two blood culture anticoagulants on growth of Neisseria meningitidis. J Clin Microbiol (1978) 0.98
Studies on neutralization of human serum bactericidal activity by sodium amylosulfate. J Clin Microbiol (1977) 0.98
Neutralization of human serum lysozyme by sodium polyanethol sulfonate but not by sodium amylosulfate. J Clin Microbiol (1978) 0.96
Evaluation of sucrose and magnesium sulfate as additives in aerobic blood culture medium. J Clin Microbiol (1981) 0.96
Controlled evaluation of modified radiometric blood culture medium supplemented with gelatin for detection of bacteremia and fungemia. J Clin Microbiol (1987) 0.93
Sodium polyanethole sulfonate as an inhibitor of activation of complement function in blood culture systems. J Clin Microbiol (2009) 0.89
Influence of a blood culture inoculation technique on detection of bacteremia by the BACTEC system. J Clin Microbiol (1982) 0.88
Variable neutralization of several nonspecific antibacterial systems in fresh, defibrinated human blood by sodium polyanetholsulfonate and sodium amylosulfate. J Clin Microbiol (1979) 0.86
Neutralization of human serum beta-lysin by sodium polyanetholsulfonate and sodium amylosulfate. J Clin Microbiol (1979) 0.79
Use of anaerobic glove boxes for the cultivation of strictly anaerobic bacteria. Am J Clin Nutr (1972) 11.38
Inactivation of the bactericidal activity of human serum by liquoid (sodium polyanetholsulfonate). Appl Microbiol (1969) 5.30
Sodium polyanethol sulfonate sensitivity of anaerobic cocci. Appl Microbiol (1974) 4.65
Effect of sodium polyanetholesulfonate on antimicrobial systems in blood. Appl Microbiol (1972) 3.72
Anticomplementary, anticoagulatory, and serum-protein precipitating activity of sodium polyanetholsulfonate. Appl Microbiol (1970) 2.96
Comparative effects of two sulfated polyanions used in blood culture on anaerobic cocci. Am J Clin Pathol (1974) 2.74
Studies on the additive effect of polymyxin B and the bactericidal activity of human serum against Serratia marcescens. Chemotherapy (1975) 1.27
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Neonatal salmonella meningitis complicated by cerebral abscesses. West J Med (1977) 5.55
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Vfr controls quorum sensing in Pseudomonas aeruginosa. J Bacteriol (1997) 3.10
Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol (1999) 2.95
Response of Neisseria gonorrhoeae to iron limitation: alterations in expression of membrane proteins without apparent siderophore production. Infect Immun (1985) 2.94
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Effect of rpoS mutation on the stress response and expression of virulence factors in Pseudomonas aeruginosa. J Bacteriol (1999) 2.72
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Aerobactin utilization by Neisseria gonorrhoeae and cloning of a genomic DNA fragment that complements Escherichia coli fhuB mutations. J Bacteriol (1987) 1.72
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50
Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun (1987) 1.47
Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47
The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46
Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45
Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39
Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36
Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34
Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20
Control of an outbreak of salmonellosis caused by drug-resistant Salmonella anatum in horses at a veterinary hospital and measures to prevent future infections. J Am Vet Med Assoc (1996) 1.19
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16
Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14
TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13
Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11
The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11
Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11
Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09
Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr (1978) 1.07
Transparent plastic incubator for the anaerobic glove box. Appl Environ Microbiol (1977) 1.06
Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect Immun (1998) 1.06
Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1994) 1.04
Breakdown of psyllium hydrocolloid by strains of Bacterioides ovatus from the human intestinal tract. Can J Microbiol (1978) 1.04
Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice. Antimicrob Agents Chemother (1975) 1.03
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Chemotherapy of an experimental Bacteroides fragilis infection in mice. Antimicrob Agents Chemother (1977) 1.01
Two patterns of neutral steroid conversion in the feces of normal North Americans. Cancer Res (1974) 1.00
Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis. J Pediatr (1984) 1.00